Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."
|Articles|November 1, 2017
UK's Medicines Discovery Catapult Launches Call for Collaboration for SMEs
Advertisement
Medicines Discovery Catapult, a new UK center established to support innovative drug discovery, is inviting UK SMEs working in medicines to collaborate on high-resolution analysis. On offer is access to an atomic resolution Solid State NMR (SSNMR) at Medicines Discovery Catapult’s facility within the University of Warwick, along with world-leading scientific support, including data analysis and interpretation. Through this Call Medicines Discovery Catapult aims to provide atomic resolution of a compound, protein structure or complex and its dynamic interactions, which are not normally amenable to resolution by other approaches. UK-registered micro, small or medium-sized enterprises engaged in drug discovery and drug re-purposing are invited to apply by Thursday November 30. Dr Peter Simpson, Chief Scientific Officer of Medicines Discovery Catapult commented: “We’re looking for innovative, dynamic partners with technically feasible proposals that will bring about significant new advances. This is an excellent opportunity for a UK SME to accelerate their R&D.” For more information, visit
https://md.catapult.org.uk/news/call-for-collaboration-SSNMR
Advertisement
Related to this article
AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
The Battle to Own the GLP-1 Patient Journey
5